President and CEO, MatriSys Bioscience, Inc.
MatriSys Bioscience – Therapeutics at the Interface of the Innate Immune System and the Skin Microbiome
MatriSys Bioscience is the first to isolate, characterize, and clinically test beneficial skin bacteria with therapeutic potential for major skin disorders. We are a clinical stage Specialty Biopharmaceutical Company focused on the immune-dermatology market. We are developing therapies for the top 5 dermatology conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. MatriSys Bio’s scientific approach is to rebalance the natural skin microbiome by application of microbial therapies - “Good Bugs” that selectively target skin pathogens - “Bad Bugs”.
Mr. Mark S. Wilson is a broadly skilled bioentrepreneur with 30 years of experience in biopharmaceutical and diagnostics development with extensive accomplishments in pharmaceutical licensing and business development, new organization startup, strategic alliance formation with Big Pharma and Big Biotech firms, and developmental sourcing in a virtual company environment. He is a Cal Berkeley Engineer with a UCLA Anderson MBA.